Navigation Links
RET rearrangement a new oncogene and potential target in lung cancer
Date:6/3/2013

In results presented at ASCO 2013, a University of Colorado Cancer Center study provides important details for a recently identified driver and target in lung adenocarcinoma: rearrangement of the gene RET. The finding is an important step along a trajectory like that which led to FDA approval of the drug crizotinib, which targets a somewhat similar rearrangement in the ALK gene. By comparison, the ALK rearrangement is present in 3-5 percent of lung cancers whereas the present study found RET rearrangements present in 8 of 51 (15.7 percent) of an enriched cohort of patient samples that did not show evidence of other oncogene alterations.

"This is an exciting finding. We know from the example of ALK-positive lung cancer that not only do rearrangements like this present druggable targets, but that at least in the case of ALK, the drugs matched to these mutations can create a stunning improvement in the lives of the targeted subset of lung cancer patients," says Marileila Garcia, PhD, investigator at the CU Cancer Center and professor at the CU School of Medicine.

The ALK mutation is targeted by crizotinib, frequently leading to improvements in patients with ALK+ lung cancer. Now it seems as if RET mutation could be targeted in a similar way, even perhaps with existing tyrosine-kinase inhibitors (TKIs) including vandetanib, sunitinib, sorafenib and ponatinib that are already used in the clinic for other tumor types.

"We're starting to pick apart these lung cancer subsets. And as we find drivers and then match them with drugs, we're increasingly able to offer treatments targeted to a specific cancer's genetic addiction. The cancer is ALK-positive? You target it with crizotinib. Now say the cancer is RET-positive? It looks promising that we may be able to target this mutation as well," says Robert C. Doebele, MD, PhD, investigator at the CU Cancer Center and assistant professor of medical oncology at the CU School of Medicine.

Specifically, the grou
'/>"/>

Contact: Erika Matich
erika.matich@ucdenver.edu
303-524-2780
University of Colorado Denver
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Tumors with ALK rearrangements can harbor more mutations
2. New oncogene identified for breast cancer
3. Dietary glucose affects the levels of a powerful oncogene in mice
4. Hepatitis B virus promotes oncogenesis through microRNA modulation
5. Preclinical study identifies master proto-oncogene that regulates ovarian cancer metastasis
6. Study identifies potential treatment for lethal childhood leukemia
7. McMaster researchers find potential for new uses of old drug
8. Army researcher develops potential vaccine carrier
9. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
10. New study of NIH funding allocations suggests potential efficiency gains
11. A closer look at PARP-1 reveals potential new drug targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... ... with Julia Glushko, professional Tennis player for Israel in the Women’s Tennis Association ... for all her training and recovery. , With a focus on technology and ...
(Date:8/27/2015)... ... August 27, 2015 , ... In addition to its existing Doctor of ... third doctoral program at its main campus in Reading: Doctor of Nursing Practice. , ... to prepare advanced practice nurses for the highest level of clinical nursing practice. ...
(Date:8/27/2015)... GREENWICH, CT and OKLAHOMA CITY, OK (PRWEB) , ... ... ... a Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract ... agreement to be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... partnership agreement for quality market research promotion on the Internet. MarketPublishers.com is ... Analysis. , Commenting on the partnership agreement, Natalie Aster, Assistant Manager at ...
(Date:8/27/2015)... TX (PRWEB) , ... August 27, 2015 , ... ... cutting edge procedure to relieve vaginal discomfort due to pre- and post-menopause, chemotherapy, and ... using a CO2 laser, which delivers controlled energy to the vaginal tissue, revitalizing cells ...
Breaking Medicine News(10 mins):Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3
... Sept. 8 , , WHAT: ... growing radio shows-- The CEO Show-- draws a clever analogy ... upcoming Webinar taken from his book titled, Golf and the Art ... the research and educational arm of Beryl, the nation,s leading healthcare-exclusive call ...
... , , , ... Health Integrated, a leading provider of Health Management Solutions, has ... the health plan integrates the management of behavioral health benefits ... solution, Health Integrated will provide Blue Cross of Idaho with ...
... , Nurses to March for Employee ... in Single-Payer Systems , , SAN ... the largest union and professional association of nurses in U.S. history, ... the biennial convention of California,s largest RN organization, the California Nurses ...
... , , LOS ANGELES, Sept. 8 ... obesity epidemic and a general lack of healthy living. In his new ... Help of a Personal Trainer" ( published by AuthorHouse ), ... lost over 60 pounds with the help of a personal trainer, and ...
... , LONDON, Sept. 8 The 2009 Frost ... Risk Management Award is presented to Pronova BioPharma ASA. The ... FDA-approved omega-3 derived prescription drug. Branded Omacor in Europe ... a prescribed adjunct to diet for the treatment of elevated ...
... , WASHINGTON, Sept. 8 /PRNewswire-USNewswire/ ... health care reform, a new analysis by the Center for ... receive benefits under the House health reform bill (H.R. 3200). ... for the new taxpayer-funded affordability credits, there is nothing in ...
Cached Medicine News:Health News:The Beryl Institute Sponsors Free Customer Service Webinar with Robert Reiss 2Health News:Health Integrated Enters into Agreement with Blue Cross of Idaho to 'Carve-in' Behavioral Health Management 2Health News:1,200 RNs Gather in San Francisco Tuesday: Take Next Step to Form Nation's Largest Ever Union of Nurses 2Health News:The Simple ABCs of Weight Loss and Fitness 2Health News:The Simple ABCs of Weight Loss and Fitness 3Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 2Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 3Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 4Health News:Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma 5Health News:Health Bill Could Benefit 6.6 Million Illegals 2Health News:Health Bill Could Benefit 6.6 Million Illegals 3
(Date:8/27/2015)... and SOUTH SAN FRANCISCO, Calif. ... Pulmonary Fibrosis Foundation (PFF) and Veracyte, ... the organizations are partnering on a U.S. patient ... with interstitial lung diseases (ILDs), including idiopathic pulmonary ... (INTENSITY) survey will assess the steps and time ...
(Date:8/27/2015)... 27, 2015  QB3@953—a San Francisco ... of California (UC) research institute and biotech accelerator— ... to identify and facilitate collaborations to translate early ... The agreement formalizes a relationship between ... team and creates a new channel for DPAc ...
(Date:8/27/2015)... , Spain and CAMBRIDGE, Mass. , Aug. 27, ... presenting at the Rodman & Renshaw 17th Annual Global Investment ... at the St. Regis Hotel, ORYZON will be represented by ... Dr. Buesa will present this ... at the Fontainebleau Room (2nd Floor).  The company is completing ...
Breaking Medicine Technology:Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 2Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 3Pulmonary Fibrosis Foundation and Veracyte Partner on Survey Exploring Diagnostic Experiences of U.S. Patients with Interstitial Lung Disease 4QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4
... EAST SETAUKET, N.Y., Dec. 19, 2011  An article in the ... of the National Academy of Sciences USA , reported ... therapeutic potential in a laboratory model of Gaucher disease  ... and president of Lixte said, "This is a novel ...
... MISSISSAUGA, Ontario, Dec. 19, 2011  Valeant Pharmaceuticals International, ... VRX) announced that effective December 16, 2011, the ... a dermatology unit of Sanofi (EURONEXT: SAN and ... International, Inc. Valeant Pharmaceuticals International, ...
Cached Medicine Technology:Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 2Lixte Biotechnology Holdings Compound LB-205 Reported to Have Therapeutic Potential for Gaucher Disease 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: